benzyl (2S,5R,8R,11S)-2-allyl-11-(4-allyloxybenzyl)-3,6,9,12-tetraaza-8-(4-[tert-butoxycarboxamido]butyl)-5-([{2,2,5,7,8-pentamethyl-3,4-dihydro-2H-6-chromenylsulfonamido}guanidino]propyl)-4,7,10,13-tetraoxotetradecanoate | 900521-71-3

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: benzyl (2S,5R,8R,11S)-2-allyl-11-(4-allyloxybenzyl)-3,6,9,12-tetraaza-8-(4-[tert-butoxycarboxamido]butyl)-5-([{2,2,5,7,8-pentamethyl-3,4-dihydro-2H-6-chromenylsulfonamido}guanidino]propyl)-4,7,10,13-tetraoxotetradecanoate
• 英文别名: Ac-Tyr(allyl)-D-Lys(Boc)-D-Arg(Pmc)-Gly(allyl)-OBn；benzyl (2S)-2-[[(2R)-2-[[(2R)-2-[[(2S)-2-acetamido-3-(4-prop-2-enoxyphenyl)propanoyl]amino]-6-[(2-methylpropan-2-yl)oxycarbonylamino]hexanoyl]amino]-5-[[amino-[(2,2,5,7,8-pentamethyl-3,4-dihydrochromen-6-yl)sulfonylamino]methylidene]amino]pentanoyl]amino]pent-4-enoate
• CAS: 900521-71-3
• 化学式: C₅₇H₈₀N₈O₁₂S
• 分子量: 1101.37
• InChiKey: CHFVULFJAPBOAV-XEOVLGQKSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  7.4
• 重原子数：
  78
• 可旋转键数：
  32
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.49
• 拓扑面积：
  292
• 氢给体数：
  7
• 氢受体数：
  13

反应信息

• 作为反应物：
  描述：

  benzyl (2S,5R,8R,11S)-2-allyl-11-(4-allyloxybenzyl)-3,6,9,12-tetraaza-8-(4-[tert-butoxycarboxamido]butyl)-5-([{2,2,5,7,8-pentamethyl-3,4-dihydro-2H-6-chromenylsulfonamido}guanidino]propyl)-4,7,10,13-tetraoxotetradecanoate 在 三氟乙酸 、 盐酸 作用下， 以 二氯甲烷 、 甲醇 、 乙醚 为溶剂， 反应 3.0h， 以85%的产率得到benzyl (2S,5R,8R,11S)-2-allyl-11-(4-allyloxybenzyl)-8-(4-aminobutyl)-3,6,9,12-tetraaza-5-(3-[guanidino]propyl)-4,7,10,13-tetraoxotetradecanoate hydrochloride
  参考文献：
  名称：

  Synthesis of novel N-protected hydrophobic phenylalanines and their application in potential antibacterials

  摘要：

  An efficient synthesis of two new N-acetyl-4'-arylphenylalanines is described together with their incorporation into a number of cationic peptoid antibacterial agents, one of which had an MIC of 7.8 mu g/mL against Staphylococcus aureus. Crown Copyright (C) 2008 Published by Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2008.07.001
• 作为产物：
  描述：

  benzyl (2S,5R,8R)-2-allyl-8-amino-3,6-diaza-12-(tert-butoxycarboxamido)-5-([{2,2,5,7,8-pentamethyl-3,4-dihydro-2H-6-chromenylsulfonamido}guanidino]propyl)-4,7-dioxododecanoate 、 O-allyl-N-acetyl-(S)-tyrosine 在 1-羟基苯并三唑 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 16.0h， 以85%的产率得到benzyl (2S,5R,8R,11S)-2-allyl-11-(4-allyloxybenzyl)-3,6,9,12-tetraaza-8-(4-[tert-butoxycarboxamido]butyl)-5-([{2,2,5,7,8-pentamethyl-3,4-dihydro-2H-6-chromenylsulfonamido}guanidino]propyl)-4,7,10,13-tetraoxotetradecanoate
  参考文献：
  名称：

  Synthesis of novel N-protected hydrophobic phenylalanines and their application in potential antibacterials

  摘要：

  An efficient synthesis of two new N-acetyl-4'-arylphenylalanines is described together with their incorporation into a number of cationic peptoid antibacterial agents, one of which had an MIC of 7.8 mu g/mL against Staphylococcus aureus. Crown Copyright (C) 2008 Published by Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2008.07.001

文献信息

• Peptidic Compounds
  申请人：Boyle Timothy Patrick

  公开号：US20080300287A1

  公开（公告）日：2008-12-04

  The present invention provides a compound of formula (I), (II), (III) and (IV) as defined herein and pharmaceutically acceptable derivatives thereof. The present invention further provides use of the compounds of the present invention in the treatment of bacterial infection and in the treatment of HIV infection. Also provided are pharmaceutical compositions comprising the compounds of the present invention.

  本发明提供了公式（I）、（II）、（III）和（IV）的化合物及其药学上可接受的衍生物。本发明进一步提供了本发明化合物在治疗细菌感染和治疗HIV感染中的用途。还提供了包含本发明化合物的制药组合物。
• US8039430B2
  申请人：——

  公开号：US8039430B2

  公开（公告）日：2011-10-18
• Synthesis of novel N-protected hydrophobic phenylalanines and their application in potential antibacterials
  作者：Timothy P. Boyle、John B. Bremner、Jonathan A. Coates、John Deadman、Paul A. Keller、Stephen G. Pyne、Kittiya Somphol

  DOI：10.1016/j.ejmech.2008.07.001

  日期：2009.3

  An efficient synthesis of two new N-acetyl-4'-arylphenylalanines is described together with their incorporation into a number of cationic peptoid antibacterial agents, one of which had an MIC of 7.8 mu g/mL against Staphylococcus aureus. Crown Copyright (C) 2008 Published by Elsevier Masson SAS. All rights reserved.